AVAREPT (Motugivatrep)

AVAREPT (motugivatrep) ophthalmic suspension 0.3%, from Senju Pharmaceutical, was approved in Japan on 22 December 2025 for dry eye disease and launched there in spring 2026. It is described as the first medicine of its class anywhere in the world.

Motugivatrep blocks TRPV1, an ion channel on the corneal nerves involved in the burning, stinging and discomfort that people with dry eye feel. By targeting this sensory pathway, it offers a new mechanism alongside conventional tear-supplementing and anti-inflammatory eye drops.

• AVAREPT is approved only in Japan; the Japanese package insert should be reviewed for dosing, side effects and contact-lens advice.
• As a suspension, the bottle should be shaken before use and the tip kept from touching the eye.
• Patients should be assessed by an ophthalmologist to confirm dry eye disease and rule out other causes.

What documents are required to import AVAREPT to India?

AVAREPT may be imported in the patient’s name only, by patients or government hospitals. The following documentation is required:

• A valid prescription from a registered ophthalmologist
• Ophthalmology report confirming dry eye disease
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription.

Is AVAREPT available in India?

AVAREPT was approved in Japan in December 2025 and is not available in India. It can be legally accessed through the Named Patient Program (NPP), subject to applicable regulations.

Indian Pharma Network (IPN) can source AVAREPT from its authorized distribution network and facilitate supply to patients, doctors, and hospitals under applicable legal provisions.

For AVAREPT cost in India and availability, contact IPN at Phone: +91-9310090915 or email info@indianpharmanetwork.in.

Global Approval Status:

• Japan: Approved — 22 December 2025.
• United States / European Union: Not approved as of October 2026.

What is AVAREPT used for?

AVAREPT (motugivatrep) is a first-in-class TRPV1 antagonist eye drop used for dry eye disease.

Who manufactures AVAREPT?

AVAREPT is from Senju Pharmaceutical (licensed from Mochida Pharmaceutical).

How does AVAREPT work?

Motugivatrep blocks TRPV1, an ion channel on the corneal nerves involved in the burning, stinging and discomfort that people with dry eye feel.

How is AVAREPT different from artificial tears?

Artificial tears replace moisture; AVAREPT targets the TRPV1 nerve channel involved in dry-eye discomfort.

Is AVAREPT approved by the US FDA?

No. It is approved in Japan only.